Abstract:Background China’s National Reimbursement Drug List (NRDL) has become the primary route for drug reimbursement in China. More recently, the authority has made pharmacoeconomic evaluation an integral part of the application for NRDL inclusion. The underlying financial conflict of interests (FCOI) of pharmacoeconomic evaluations, however, has the potential to influence evidence generated and thus subsequent decision-making yet remains poorly understood. Methods We searched for studies published between January 2012 and January 2022 on the 174 drugs added to the 2017–2020 NRDLs after successful negotiation. We categorised the study’s FCOI status into no funding, industry funding, non-profit funding and multiple fundings based on authors’ disclosure and assessed the reporting quality of included studies using the Consolidated Health Economic Evaluation Reporting Standards 2022 checklist. We compiled descriptive statistics of funding types and study outcomes using t-tests and χ 2 tests and conducted multivariate regression analysis. Results We identified 378 records and our final sample included 92 pharmacoeconomic evaluations, among which 69.6% were conducted with at least one funding source. More than half (57.6%) of the evaluations reached favourable conclusions towards the intervention drug and 12.6% reached a dominant result of the intervention drug over the comparison from model simulation. The reporting quality of included studies ranged from 19 to 25 (on a scale of 28), with an average of 22.3. The statistical tests indicated that industry-funded studies were significantly more likely to conclude that the intervention therapy was economical (p<0.01) and had a significantly higher proportion of resulting target drug economically dominated the comparison drug (p<0.05). Conclusion The study revealed that FCOI bias is common in published pharmacoeconomic evaluations conducted in Chinese settings and could significantly influence the study’s economical results and conclusions through various mechanisms. Multifaceted efforts are needed to improve transparency, comparability and reporting standardisation.

A knowledge-attitude-practice investigation of pharmacoeconomics in different stakeholders

A Critical Review of Chinese Pharmacoeconomics Studies in the Last Five Years.

Systems analysis and evaluation of Chinese pharmacoeconomic literatures over ifve years

Differences In Evaluating Health Technology Assessment Knowledge Translation By Researchers And Policy Makers In China

Quality of Pharmacoeconomic Research in China: A Systematic Review

International Experience of Pharmacoeconomic Evaluation in Health Decision-making

Determinants Of Knowledge Translation From Health Technology Assessment To Policy-Making In China: From The Perspective Of Researchers

Assessment of the quality of pharmacoeconomic evaluation literature in China

Health Technology Assessment and Its Use in Drug Policies in China

[Expert consensus on pharmacoeconomic evaluations alongside clinical trials (2024 edition)]

Comparative analysis of knowledge translation of health technology assessment research between different types of research institues

Assessment and predictive analysis of health professions students' proficiency in health economics and pharmacoeconomics in Southwest China: a cross-sectional study

Introduction to knowledge translation from health technology assessment to health policy in China

The development status of systematic reviews in pharmacoeconomics ifeld

Conducting Pharmacoeconomics Studies to Provide Service for the Sustainable Development of Medical Insurance System

Survey and Analysis of Clinical Researchers' Knowledge, Attitude and Practice (KAP) about Ethical Review

Development and Practice of Pharmacoeconomics in Aisa-Pacific Region

Cross-sectional study of pharmacovigilance knowledge, attitudes, and practices based on structural equation modeling and network analysis: a case study of healthcare personnel and the public in Yunnan Province

Bibliometric Analysis of Foreign Pharmacoeconomic Literatures

Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review

Specific Role of Pharmacoeconomics in the Medical Reform Program Implementation